Lesley Solomon, M.B.A.
Ruslan's vision around food allergy and the FASI team's support of it will change the world. The way the scientists are thinking about food allergies now versus the way they were looking at them five years ago is more mechanistic and systemic in a way that can only create real impact for patients. I am thrilled to be part of this effort in support of my food allergic son and millions of others across the globe.
Lesley Solomon became Dana-Farber’s first SVP and Chief Innovation Officer in 2017. She previously served as the founding executive director of Brigham and Women’s Innovation Hub and as director of strategy and innovation in the Brigham Research Institute.
Lesley leads a team focused on commercializing DFCI’s science and technology, working with industry, academic, and investment partners to accelerate the pace of getting that work to patients. She thrives on developing innovative models for partnerships to sustain the Institute’s research funding and is creating new ways to expand the reach of DFCI’s clinical care.
At Dana-Farber, 36 members of the innovation transfer office report up to Lesley through five directors covering finance/operations, licensing and contracts, business development, an accelerator, and Dana-Farber’s first internal investment fund, Binney Street Capital. At Brigham and Women’s, Lesley led a team of 8 people focused on two core areas; supporting Brigham faculty with ideas on care improvement that needed help moving those ideas into design thinking to identify the problems and begin to develop solutions.
Lesley has more than 25 years of experience as an executive working in business development, strategy, and marketing at startups, early-stage, and large companies such as the Food Network, Barnes & Noble.com, and Yoga Works. She received her MBA from Harvard Business School and has a BA in English from Cornell University. She is a co-founder of the Food Allergy Science Initiative, which brings together experts across disciplines to unlock the biology of food allergy and change the field to develop new treatments. As co-founder, she has been involved in growing FASI into a $30M effort that is now partnering with biotechs and a new investment fund to create further momentum in the food allergy field. Lesley is a founding advisor of this investment fund (AllerFund) as well as an advisor at Firefly Health, a health tech company that aims to disrupt primary care and provide better care to patients across the US.
Lesley received the 2020 Extraordinary Women Advancing Healthcare Award by The Commonwealth Institute and was named a 2020 Woman to Watch in IT by Becker’s Hospital Review. She is also the mother of a son with food allergies.